Background A 56-year-old male with a history of excess alcohol consumption for over 10 years and type 2 diabetes mellitus (diagnosed 14 years previously) presented to the accident and emergency ...

C3b alone does not mediate cytotoxicity or phagocytosis but greatly enhances IgG-induced phagocytosis or cytotoxicity through adherence to the complement receptors (for C3b only) on mononuclear cells.

Cold antibody hemolytic anemia may also occur as a secondary disorder in association with a number of different underlying disorders, such as certain infectious diseases (e.g., mycoplasma infection ...

Antimicrobial polymers have emerged as a potential solution to the growing problem of antimicrobial resistance. Although several studies have examined the effects of various parameters on the ...

INTRODUCTION Anemia, defined as hemoglobin (Hb) ≤ 12 g/dL in women and Hb ≤ 13 g/dL in men 1, was first linked to chronic kidney disease (CKD) in 1836 by Richard Bright 2. This condition is highly ...

Iron deficiency is a worldwide problem—and your body can do some weird things when you don't get enough. Here are the signs you might have iron deficiency and how to meet your daily intake.

(Left) Pre-ignition (below the activation threshold) Only a handful of immune "tags" (C3b proteins) cover the nanoparticle, so it barely sticks to the white membrane—too few contact points means ...

Four subsequent episodes of anemia (Relapses III, IV, VI and VII, Fig. 2) were terminated after the administration of 50 or 100 mg. of pyridoxine hydrochloride subcutaneously.

Mixed autoimmune hemolytic anemia (AIHA) was a rare and complex disorder characterized by both warm and cold autoantibodies causing severe, often treatment-resistant hemolysis, with limited data ...

Anemia treatments involve controlling ulcerative colitis inflammation through trigger avoidance, medications, or surgery, and replenishing iron, vitamin B12, or folate levels, depending on the ...

First-line luspatercept may offer significant advantages over erythropoiesis-stimulating agents (ESAs) for anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS), according to a ...